MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Personalized Medicine_Genetic Testing & Data Sets
23andMe Holding Co. (NASDAQ: ME)*
Organization & Developments: 23andMe
Parents
23andMe Holding Co. (NASDAQ: ME)*
Children
2011: 23andMe offering 10,000 free gene tests - Silicon Valley (2011)
2013: FDA Tells Google Inc Backed 23andMe Inc To Halt (2013)
2014: 23andMe to open database to external researchers after securing NIH grant
2014: Genetics startup 23andMe takes step on path to FDA approval
2015: 23andMe finally gets a nod from FDA
2015: 23andMe strikes $60M Genentech deal to continue pivot to database-driven R&D
2015: 23andMe To Leverage Database for Drug Research, Development
2015: FDA clears way for 23andMe to roll out health-related genetic testing
2017: 23andMe to launch study exploring role of genetics in depression, bipolar disorders
2017: FDA OKs 23andMe’s Direct-to-Consumer Genetic Tests, With Caution
2020: 23andMe cuts 100 jobs amidst slowing demand
2021: 23andMe jumps into telehealth, prescription drug delivery with $400M buyout of Lemonaid Health
2022: 23andMe betting big on its genomic health service that integrates genetics with primary care
2022: 23andMe: Strong Genomics Quarter But Cash Burn Is Huge_ seekingalpha.com
2023: 23andMe Lays off 71 Therapeutics-Related Employees as GSK Partnership Ends, Q1 Revenues Slide
2024: 23andMe cuts 40% of its workforce, discontinues all therapy programs
2024: 23andMe data breach may have targeted those of Jewish and Chinese heritage; company valuation crashes (updated)
2024: 23andMe independent board directors resign en masse
2024: 23andMe’s independent board directors resign
2024: The rise and fall of 23andMe
2024: What happens to all of 23andMe's genetic DNA data?
2024: With 23andMe's Directors Quitting, Your Data is at Risk
2025: 23andMe Files for Bankruptcy Amid Concerns About Security of Customers’ Genetic Data_ www.nytimes.com
2025: 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
2025: What went wrong at 23andMe? Why the genetic-data giant risks collapse
23andMe is a leading consumer genetics and research company that offers a personalized health-and-wellness experience that has built a genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development.
23andMe’s Personal Genome Service® enables individuals to explore their own DNA and currently provides more than 200 health and traits reports as well as genetic ancestry information.
Jumps
*Key People: 23andMe
Finance & Acquisitions: 23andMe